Trial Profile
Prospective Analysis of an individualized dosing Regimen of ATG (Thymoglobulin) in Children Undergoing HCT: redUcing Toxicity and improving Efficacy – a single arm phase II study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Aug 2021
Price :
$35
*
At a glance
- Drugs Antithymocyte globulin (Primary)
- Indications Graft-versus-host disease; Immunodeficiency disorders; Leukaemia
- Focus Pharmacodynamics
- Acronyms PARACHUTE
- 20 Jun 2020 Status changed from not yet recruiting to completed.
- 10 Mar 2015 New source identified and integrated as Netherlands Trial Register (NTR4960).
- 24 Feb 2015 New trial record